ArticleActa neurologica Belgica2025
Coexistence of anti-MOG and anti-MAG antibodies in combined central and peripheral nervous system demyelination: a case of dual myelinopathy.
Article in Acta neurologica Belgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyelin oligodendrocyte glycoprotein-associated disease (MOG-AD) is a central nervous system (CNS) demyelinating disorder linked to anti-MOG antibodies, whereas anti-myelin associated glycoprotein (MAG) antibodies are associated with peripheral nervous system (PNS) demyelination. Their coexistence in a single patient has not been previously reported. CASE PRESENTATION: We describe a 38-year-old male who developed rapidly progressive paraparesis, visual impairment, and sensory deficits. MRI revealed multifocal CNS demyelinating lesions, while nerve conduction studies later confirmed a demyelinating polyneuropathy. Serum testing showed concurrent anti-MOG and high-titer anti-MAG antibodies. Despite treatment with corticosteroids, IVIg, and plasma exchange, the patient exhibited a severe, relapsing course with persistent disability.
conclusionThis is the first documented case of anti-MOG and anti-MAG antibody coexistence, causing simultaneous CNS and PNS demyelination and suggesting a shared autoimmune mechanism. Anti-MAG antibodies may indicate a more aggressive course, warranting routine testing and intensive therapy. Further research is needed to clarify their pathogenic interplay and refine treatment strategies.
Indexed as
Identifiers
40418511What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.